TIL Therapy for Melanoma — A New Option When Other Treatments Don’t Work

​

Melanoma is an aggressive skin cancer that can spread quickly. For people with advanced or treatment‑resistant melanoma, Tumor‑Infiltrating Lymphocyte (TIL) therapy is an exciting immunotherapy that uses a patient’s own immune cells to attack the cancer. TIL treatment for melanoma has shown strong results in clinical studies and is now an FDA‑approved option for certain patients.

 

What is TIL therapy for melanoma?

​

Tumor‑Infiltrating Lymphocyte (TIL) therapy takes immune cells that are already inside a patient’s tumor, grows them to large numbers in a lab, and returns them to the body to find and kill melanoma cells. Because these cells come from the patient’s own tumor, they’re already “trained” to recognize that cancer.

 

How TIL treatment for melanoma works 

​

​

​​

• Tumor sample — Doctors remove a small piece of the tumor during a biopsy or surgery.

• Lab growth — Lab teams isolate the TILs, pick the most active ones, and expand them (often using IL‑2) until there are billions.

• Prep treatment — The patient gets a short course of chemotherapy (called lymphodepletion) to make room for the new TILs.

• Infusion — The TILs are given back through an IV; IL‑2 may be given afterward to help the cells survive.

• Follow‑up — Doctors monitor response and manage side effects with scans and clinic visits.

 

Typical timeline: ~3–8 weeks from tumor removal to infusion (varies by program).

​

​

​

​

​

​

​

 

 

 

Why consider TIL therapy for melanoma?

​

• Works after other treatments fail. TIL therapy has helped patients who did not respond to PD‑1 checkpoint inhibitors (e.g., Keytruda).

• Personalized approach. The therapy uses your own immune cells to target your tumor.

• Durable responses. Some patients have long‑lasting tumor control after a single TIL infusion.

• FDA-approved option. Lifileucel (brand name Amtagvi) received FDA approval for adults with unresectable or metastatic melanoma after prior PD‑1 treatment.

 

What the studies show 

​

Clinical trials of TIL therapy in advanced melanoma have shown meaningful response rates (many trials report response rates in the ~30–50% range for selected patients). Some studies — and combination approaches — have reported higher response rates in specific groups. The phase III M14TIL trial and other studies have demonstrated benefits in progression‑free survival for certain patients with advanced melanoma. Lifileucel’s approval was based on phase 2 and supportive trial data showing substantial responses in patients who had few other treatment options. Note: Results vary by trial and patient group. Talk with your oncologist about what the data mean for your case.

 

Side effects & safety (what to expect)

​

• Common: fever, fatigue, nausea, low blood counts (from prep chemo).

• Serious but less common: strong immune reactions (e.g., cytokine release syndrome) that need hospital care.

• Monitoring: TIL programs typically require inpatient monitoring during and after infusion until early side effects are controlled.

 

Who might be eligible?

​

• Adults with unresectable or metastatic melanoma who were previously treated with a PD‑1 inhibitor.

• Patients whose tumors can provide enough TILs for lab expansion.

• Eligibility depends on overall health, tumor status, and prior treatments — ask your oncologist.

 

How to find treatment or trials

​

Ask your oncologist about lifileucel (Amtagvi) and whether you may qualify. Search clinical trial registries and specialized cancer centers for TIL therapy programs. Some centers and companies now offer TIL programs or trials for melanoma and other solid tumors.

 

Quick questions to ask your doctor

​

1. Am I a candidate for TIL therapy or a clinical trial?

2. Can my tumor provide enough cells to grow TILs?

3. What side effects should I expect, and how will you manage them?

4. How long will it take from tumor surgery to infusion?

5. Where is TIL treatment offered and will insurance cover it?

 

Sources

1. FDA — Lifileucel (Amtagvi) approval (Feb 16, 2024) — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma

2. National Cancer Institute — NCI article on Lifileucel (2024) — https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-amtagvi-til-therapy-melanoma

3. Journal of Clinical Oncology / ASCO — example study on lifileucel — https://ascopubs.org/doi/10.1200/JCO.21.00612

4. Netherlands Cancer Institute — M14TIL trial results — https://www.nki.nl/news-events/news/til-therapy-meets-primary-endpoint-of-progression-free-survival-in-melanoma/

5. AACR — FDA approves first TIL therapy (patient-friendly) — https://www.aacr.org/patients-caregivers/progress-against-cancer/fda-approves-first-tumor-infiltrating-lymphocyte-therapy/